PROBILIFT Acute & Daily Capsules

6-Strain Probiotic for Digestive Health

Probiotics are beneficial bacteria essential for improving intestinal health. Certain medication or disease states can affect microflora and therefore increase the risk and susceptibility of gut infections1. ProbiLIFT Capsules are probiotic supplements specially formulated with 6 probiotic strains. By supplementing your diet with Probilift Capsules, you can strengthen your barrier effect to keep you healthy2.
Probiotics can increase the levels of beneficial bacteria in the gut, creating an environment that is unfavourable to the growth of harmful bacteria. By introducing live probiotic cultures to the intestinal tract, the beneficial gut flora populations are increased and transitory flora, including pathogenic or bad bacteria, are not able to colonise within the intestines2.

What do ProbiLIFT Capsules do?

  • Fights the growth of harmful bacteria

  • Supports the immune system

  • Supports a healthy gut

ProbiLIFT Capsules can replace the good bacteria lost through:

  • Antibiotic treatment3

  • Diarrhoea & Constipation4,5

  • GI infection2

  • Old Age11

  • Malnutrition

Probiotics can assist in:

  • Reducing the side effects of antibiotic treatment3

  • Minimising GI discomfort and bloating associated with IBS (irritable bowel syndrome), IBD (inflammatory bowel disease) & colitis (intestinal inflammation)8,9

  • Prevention and treatment of allergic skin reactions and eczema10

Why 6 strains?

The beneficial effects of probiotics are both strain- and dose-specific. A combination of various probiotic strains working together has been shown to be the most effective
in the gut6. In addition, more significant results can be achieved with multiple strains in combination compared to single strain preparations7.

How to Use:

If you are taking antibiotics, you may increase the dose to 1 capsule three times daily for the duration of the course of antibiotics and up to three days after the course is finished. Do not use probiotics and antibiotics simultaneously. 

Preservative, sugar, flavouring and colourant free.

Do not exceed the recommended daily dosage.
Always tell your healthcare professional if you are taking other medicines on a regular basis, including complementary or traditional medicines.
Safety for use during pregnancy and lactation has not been established.
Porphyria: Safety has not been established.
Do not use when known sensitivity or allergy exists towards any of the ingredients.
STORE OUT OF SIGHT AND REACH OF CHILDREN
This medicine has not been evaluated by the South African Health Product Regulatory Authority (SAHPRA) for its efficacy and intended use.
This medicine is not intended to diagnose, treat, cure or prevent any disease.

DOSAGE AND DIRECTIONS FOR USE:
Adults:  One capsule daily

Ingredients:
Active substances per capsule:
1 billion CFU* probiotics consisting of a blend of:
Bifidobacterium lactis BI-07® 200 million CFU
Bifidobacterium longum BI-05® 150 million CFU
Lactobacillus acidophilus La-14® 200 million CFU
Lactobacillus reuteri 1E1 150 million CFU
Lactobacillus rhamnosus Lr-32® 150 million CFU
Lactobacillus salivarius Ls-33® 150 million CFU

*CFU – Colony Forming Units
Inactive Ingredients:
Medium Chain Triglyceride (MCT) oil and silicon dioxide.

Detailed Information:
Scheduling status: S0. Proprietary name (and dosage form): PROBILIFT ACUTE & DAILY (capsules). Pharmacological classification: D.34.9 Probiotic. Complementary Medicine. Health Supplement. Pharmacological action: Probiotics are beneficial bacteria, essential for improving intestinal health. Certain medication or disease states can affect microflora and therefore increase the risk and susceptibility of gut infections. PROBILIFT is a probiotic supplement specially formulated with 6 probiotic strains. By supplementing your diet with PROBILIFT, you can strengthen your barrier effect to keep you healthy. Probiotics can increase the levels of beneficial bacteria in the gut, creating an environment that is unfavourable to the growth of harmful bacteria. By introducing live probiotic cultures to the intestinal tract, the beneficial gut flora populations are increased and transitory flora, including pathogenic or bad bacteria, are not able to colonise the intestine. Identification: PROBILIFT is opaque white gelatine capsules filled with a white to off-white powder. Presentation PROBILIFT is supplied as 10 & 30 capsules packed in a PVDC/aluminium blister. Agera Health. info@agerapharma.co.za | www.agerahealth.co.za 10 & 30 Capsules.

Resources:

  1. Binns, N. (2013) Probiotics, Prebiotics and the Gut Microbiota. ILSI Europe Concise Monograph Series.
  2. Fooks, L. J., Fuller, R., Gibson, G. R. (1999). Prebiotics, probiotics and human gut microbiology. International Dairy Journal, 9, 53-61.
  3. Kyne, L., Kelly, C. P. (2001). Recurrent Clostridium difficile diarrhoea. Gut, 49, 152–153.
  4. Sazawal, S., Hiremath, G., Dhingra, U., Malik, P., Deb, S, Black, R. E. (2006). Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. The Lancet Infectious Diseases, 6(6), 374 –382.
  5. Guandalini, S. (2006). Probiotics for children: use in diarrhea. Journal of Clinical Gastroenterology, 40(3), 244–248.
  6. Timmerman, H. M., Koning, C. J., Mulder, L., Rombouts, F. M., Beynen, A. C. (2004). Monostrain, multistrain and multispecies probiotics: a comparison of functionality and efficacy. International Journal of Food Microbiology, 96(3), 219-233.
  7. Leyer, G. J., Li, S., Mubasher, M. E., Reifer, C., Arthur C. Ouwehand, A. C. (2009). Probiotic Effects on Cold and Influenza-Like Symptom Incidence and Duration in Children. Pediatrics, 124, 172-179.
  8. Ringel, Y., Ringel-Kulka, T., Maier, D., Carroll, I., Galanko, J. A., Leyer, G., Palsson, O. S. (2011). Clinical trial: Probiotic Bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 Versus Placebo for the Symptoms of Bloating in Patients with Functional Bowel Disorders – a Double-Blind Study. Journal of Clinical Gastroenterology, 45(6), 518–525.
  9. Van der Kleij, H., O’Mahony, C., Shanahan, F., O’Mahony, L., Bienenstock, J. (2008). Protective effects of Lactobacillus reuteri and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve. American Journal of Physiology- Regulatory, Integrative & Comparative Physiology, 295, 1131–1137.
  10. Rautava, S., Kalliomaki, M., Isolauri, E. (2005). New therapeutic strategy for combating the increasing burden of allergic disease: probiotics: a Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI) Research Group report. Journal of Allergy & Clinical Immunology, 116(1), 31–37.
  11. Biagi, E., Candela, M., Fairweather-Tait, S., (2012). Aging of the human metaorganism: the microbial counterpart. Age, 34, 247–267.